AACR 92nd Annual Meeting • March 24-28, 2001 • Ernest N. Morial Convention Center • New Orleans, LA
Letter from the President:
Dear Colleagues:
This is a time of great change in cancer research. We are witnessing some of the first positive results of the application of treatment strategies derived from cutting-edge research. New therapeutic targets have been uncovered from studies of the intricate signaling pathways that control cell growth and differentiation. Traditional disciplines are embracing revolutionary new technologies, and the boundaries between fields are becoming less apparent. A myriad of compounds with unique properties is being generated at the interface of chemistry and biology. The human genome is an open book, and the language of bioinformatics is providing a Rosetta stone for biology. There is a strong feeling that the tide of the battle is finally turning in our favor, and researchers are inspired by the fact that the science they are doing today will have a direct impact in the clinic. However, we are still confronted by the complexity of cancer, and we are challenged by the great need for much improved therapies.
The guiding principle of AACR is to foster the highest quality research
to accelerate the prevention and cure of cancer. The AACR Annual Meeting
provides the only setting where scientists can be exposed to the latest
advances in their particular disciplines while having an opportunity to
learn about the broader
scope of cancer research from diverse perspectives. I am very excited
about the 2001 meeting. More than at any time in the past, there is a great
need for the integration and assimilation of new concepts. At the Annual
Meeting, laboratory-based scientists will interact with clinical researchers
to improve the translation of ideas into therapies and successful chemoprevention
strategies. Industry, academia, and government scientists will work together
to develop better anticancer drugs. The research community will learn from
the dedication and support provided by survivors and advocates. In the
Public Forum, scientists will reach out to the general public to inform
them about cancer research, to answer their questions, and to respond to
their concerns. Clearly, the Annual Meeting provides a perfect venue for
establishing and strengthening partnerships across all constituencies in
the fight against cancer.
I look forward to sharing ideas and learning from you next March in New Orleans at the AACR’s most important scientific event of the year.
Yours sincerely,
Tom Curran, Ph.D.
As the secrets of the human genome unravel, we are poised to take advantage of a wealth of new information and technological advances to prevent and cure cancer. Stanley J. Korsmeyer and our outstanding Program Committee are developing a tremendously exciting program for the 92nd AACR Annual Meeting. The meeting is focused on the highest quality fundamental and translational cancer research. The following partial list of topics provides examples of areas that will be addressed during the meeting. The latest scientific breakthroughs and the translation of these findings into new therapies in the clinic as well as novel strategies for prevention will be presented under each of these topics.
Perspectives on the Human Genome and Cancer
Gene Expression Profiling
Human Cancer Genetics
Animal Models
Small Molecules for Molecular Targets
Molecular Targeted Cancer Therapeutics
Tumor Suppressor Genes and Therapeutics
In Vivo Imaging
Subcellular Trafficking
Adhesion Molecules
Extracellular Matrix
Protein Degradation, Ubiquitin, and Proteasome
Angiogenesis
Cell Cycle
DNA Repair Mechanisms
Cellular Senescence
Antibody-based Therapeutics
Molecular Diagnostics and Detection
Chromatin and Nuclear Organization
Molecular Approaches to Population Studies
Prevention of Breast Cancer: Molecules to Clinical Trials
Nervous System Tumors
Hypoxia and Cancer
Stem Cell Biology
Prostate Cancer
Behavorial Genetics
Studies in Cancer Survivors
Chromosomal Translocations in Hematopoietic Malignancies: Causation
to Therapeutics
Viruses in Cancer
Transcription Factors in Cancer
Signal Transduction
Proteins That Inhibit Cell Cycle Kinases
Modification of ras Proteins
PTEN and Downstream Effectors
Bone Marrow Transplantation
Pharmacogenomics
Checkpoints and DNA Damage
IGF-related Proteins as Biomarkers in Chemoprevention
Proteomics
Signaling in Benign Breast Disease
Jak STAT Signaling
Apoptosis
Drug Resistance Mechanisms
Etiology of Adult Leukemias
Genomic Instability
Cancer and the Microenvironment
The p53 Family
Genetic Imprinting
Bioinformatics
Mechanisms of Carcinogenesis
Antisense Strategies
Breast Cancer
Gene Regulation
Telomerase and Cancer
Treatment of Intraepithelial Neoplasia
Gene-Environment Interactions
Gene Therapy: Where Do We Go from Here?
Cancer Screening
Watch for the Preliminary Program for additional topics in all areas of basic, translational, and clinical research.
American Association for Cancer Research
Public Ledger Building, Suite 826
150 S. Independence Mall West
Philadelphia, PA 19106-3483
Telephone: +1 215 440 9300
FAX: +1 215 351 9165
E-mail: meetings@aacr.org
WebSite: http://www.aacr.org/